

## Bimodal and Multiscale <sup>19</sup>F-MRI-Raman Detection of Fluorinated Nanoparticles for the *in-situ* Detection of Tumoral Lesions

**Benedetta Gavazzoni**<sup>1,2\*</sup>, **Francesco Manna**<sup>1,2</sup>, **Beatrice Lucia Bona**<sup>3</sup>, **Francesca Garello**<sup>4</sup>, **Cristina Chirizzi**<sup>5</sup>, **Alberto Lux**<sup>6</sup>, **Dario Polli**<sup>2</sup>, **Giulio Cerullo**<sup>2</sup>, **Giuseppe Digilio**<sup>7</sup>, **Claudia Conti**<sup>6</sup>, **Francesca Baldelli Bombelli**<sup>3</sup>, **Renzo Vanna**<sup>1</sup>

*1 Institute for Photonics and Nanotechnologies, Consiglio Nazionale delle Ricerche (CNR-IFN); 2 Department of Physics, Politecnico di Milano, Milan, Italy; 3 Department of Chemistry, Materials, and Chemical Engineering “Giulio Natta”, Politecnico di Milano, Milan, Italy; 4 Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy; 5 IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 6 Institute of Heritage Science, Consiglio Nazionale delle Ricerche (CNR-ISPC); 7 Department of Science and Technological Innovation, Università del Piemonte Orientale, Alessandria, Italy*

\* [benedetta.gavazzoni@polimi.it](mailto:benedetta.gavazzoni@polimi.it)

**Keywords:** tumoral margins, <sup>19</sup>F-MRI-Raman multiscale approach, fluorinated nanoparticles

The failure to accurately detect tumoral margins during surgery is responsible for the need for a second surgical intervention in 3-40% of cases, associated with worse prognosis, patient’s discomfort and increased costs for the healthcare systems. The possibility of combining contrast agent-based tumor-targeting MRI imaging strategies with techniques enabling the intraoperative *in-situ* detection of the very same contrast agent would allow the accurate identification of the tumoral lesion, thereby improving surgical timing and reducing recurrence.

Here we present a bimodal and multiscale approach for the detection of fluorinated nanoparticles (FNPs) *in-vivo* by <sup>19</sup>F-MRI imaging at whole body scale, and for the subsequent *in situ* detection of the same nanoparticles at their site of accumulation (e.g., after tumor targeting) using Raman spectroscopy, with sub-millimeter accuracy.

FNPs, made starting from PLGA nanocarriers loaded with PERFECTA, a perfluorinated molecular probe characterized by exceptional <sup>19</sup>F MRI sensitivity and distinct Raman signatures [1], were first stabilized with either polyvinyl alcohol (PVA) or sodium cholate (NaC). *In vitro* Raman imaging was used to monitor FNPs uptake in NIH/3T3 murine fibroblasts. Measurements were carried out with a home-built Raman micro-spectroscopy system (660 nm excitation wavelength), enabling hyperspectral imaging throughout the cell volume (step size = 0.7 μm; pixel dwell time = 750 ms). Raman imaging revealed the time-dependent internalization of FNPs, allowing the separate tracking of their fate, and, furthermore, the eventual degradation of both the fluorinated core and the PLGA-based carrier, independently, thanks to specific Raman signals of these two molecules.

Subsequently, FNPs were administered, intratumorally or intravenously, in BALB/c mice bearing orthotopic mammary tumors and detected by *in-vivo* <sup>19</sup>F-MRI. After MRI experiments, Raman detection of FNPs was confirmed on intact tumors both *in situ* (within the euthanized animal) and *ex vivo* after surgical excision, on high-MRI signal sites. Scattered photons coming from depths of up to 2.5 mm were collected using both SORS and micro-SORS strategies, based on 785 nm excitation. Further analysis will be conducted on tissue sections obtained from intravenously injected tumor-bearing mice to investigate the depth-dependent distribution and internalization of PERFECTA within the tumor microenvironment.

Our bimodal and multiscale approach opens the door to future *in vivo* investigations: PERFECTA-based FNPs could be used to identify tumor localization via <sup>19</sup>F-MRI, followed by *in situ* and *in vivo* characterization of tumor margins using portable SORS devices equipped with fiber-optic probes, supporting intraoperative detection of residual cancer cells.

**References**

[1] Chirizzi, Cristina, et al. "A bioorthogonal probe for multiscale imaging by  $^{19}\text{F}$ -MRI and Raman Microscopy: from whole body to single cells". (2021)